Vol. 91, Issue 5, 1948-1954, November 2001
Pulmonary arterial dilation by inhaled NO: arterial diameter,
NO concentration relationship
Jason
Bentley1,
David
Rickaby1,
Steven T.
Haworth1,
Christopher C.
Hanger2, and
Christopher A.
Dawson1,3,4
Departments of 1 Physiology, and 2 Anesthesiology,
Medical College of Wisconsin, Milwaukee 53226; 3 Department of
Biomedical Engineering, Marquette University, Milwaukee 53201; and
4 Research Service, Zablocki Veterans Affairs Medical Center,
Milwaukee, Wisconsin 53593
 |
ABSTRACT |
The objective of this study was to
determine the nitric oxide (NO) concentration and vessel diameter
dependence of the pulmonary arterial dilation induced by inhaled
NO. Isolated dog lung lobes were situated between a microfocal
X-ray source and X-ray detector and perfused with either blood or
plasma. Boluses of radiopaque contrast medium were injected into the
lobar artery under control conditions, when the pulmonary arteries were
constricted by infusion of serotonin and when the serotonin infusion
was accompanied by inhalation of from 30 to 960 parts/million NO.
Arterial diameter measurements were obtained from X-ray images of
vessels having control diameters in the 300- to 3,400-µm range.
Serotonin constricted the vessels throughout the size range studied,
with an average decrease in diameter of ~20%. The fractional
reversal of the serotonin-induced constriction by inhaled NO was
directly proportional to inhaled NO concentration, inversely
proportional to vessel size, and greater with plasma than with blood
perfusion in vessels as large as 3 mm in diameter. The latter indicates
that intravascular hemoglobin affected the bronchoalveolar-to-arterial
luminal NO concentration gradient in fairly large pulmonary arteries.
The data provide information regarding pulmonary arterial smooth muscle
accessibility to intrapulmonary gas that should be useful as part of
the database for modeling the communication between intrapulmonary gas
and pulmonary arterial smooth muscle cells in future studies.
serotonin; pulmonary vascular resistance; pulmonary X-ray
angiography; dog lung; nitric oxide
 |
INTRODUCTION |
PULMONARY
ARTERIAL SMOOTH muscle tone is under the influence of pulmonary
gas composition, such that a decrease from normal alveolar
PO2 causes constriction (1, 12, 18,
28), variations in alveolar PCO2 have
modulating effects (11, 27), and inhaled nitric oxide (NO)
causes dilation (10, 21-25, 28). For hypoxic vasoconstriction, the most prevalent current view appears to be that
the sensor mediating the PO2 effect is within
the vascular smooth muscle cells themselves (16, 17, 30)
and that alveolar rather than pulmonary arterial
PO2 is the dominant stimulus (7, 12,
18). The reason for the latter is not entirely clear, because,
whereas the muscular arteries are in fairly close proximity to alveolar
and bronchial air, the distances between these air spaces and arterial
smooth muscle cells appear to be at least as long as between smooth
muscle cells and luminal blood (20). Significant gas
exchange is thought to take place primarily within the pulmonary
capillaries downstream from the muscular arteries (9, 26).
However, some gas exchange apparently occurs in larger vessels
(5, 15). Thus the question arises as to where the
pulmonary arterial vascular smooth muscle lies along the gradient in
gas tensions between bronchoalveolar gas and intra-arterial blood
(12).
NO also acts directly on the smooth muscle cell (14). Thus
its efficacy as an inhaled pulmonary vasodilator presumably depends on
its ability to reach arterial smooth muscle cells with tone via the
intrapulmonary gas. Dilation of pulmonary arteries as small as 35 µm
(13) and as large as 1 mm (28) by inhaled NO has been observed. However, the relationship between inhaled NO concentration and the arterial diameter dependence of its accessibility to the smooth muscle within the vessel wall has not been specifically evaluated. The strategy of the present study was to constrict the
pulmonary arteries in isolated dog lungs using a stimulus (serotonin
infusion) that would constrict vessels over a broad range of diameters
(1) and then to determine, using microfocal X-ray
angiography, the vessel diameter dependence of the relationship between
the vasodilatory response to inhaled NO and the inhaled NO
concentration. We also examined whether using blood cell-free plasma
instead of whole blood to perfuse the lungs, i.e., varying the
intravascular NO sink (14) and, therefore, potentially
varying the intrapulmonary gas to intravascular NO gradient, would
affect the diameter dependence of the dilator response vs. NO
concentration relationship. A key objective was to provide additional
information regarding pulmonary arterial smooth muscle accessibility to
intrapulmonary gas as part of the database for modeling the
communication between intrapulmonary gas and pulmonary arterial smooth
muscle cells in future studies.
 |
METHODS |
X-ray angiographic image data were obtained from perfused dog
lung lobes prepared as previously described (1). Each of 15 dogs [13.3 ± 4.6 (SD) kg body wt] was anesthetized with
pentobarbital sodium (30 mg/kg iv), heparinized (1,250 IU/kg), and
exsanguinated via a carotid artery catheter. During the exsanguination
procedure, ~12 ml/kg of saline solution containing 10% dextran
(Rheomacrodex, 40 kDa) were infused. After exsanguination, the chest
was opened, and cannulas were placed in the left lower lobar artery,
vein, and bronchus. The lobe was excised and suspended from the
bronchus between an X-ray source (Fein Focus FXE-100.20; 3-µm focal
spot) and a detection system (North American Imaging X-ray image
intensifier with Sony charge-coupled device camera) as previously
described (3). The lobar artery and vein were connected to
the temperature-controlled (35°C) perfusion system primed with a
volume of ~1 liter of either autologous blood (Hct = 32.7 ± 2.8; n = 7) or a mixture of autologous and
homologous plasma (n = 8). A roller pump (Masterflex)
pumped the blood or plasma from a reservoir into the lobar artery at a
flow rate of 12.2 ± 1.9 (SD)
ml · min
1g
1 lobe wet weight for
lobes weighing 31.1 ± 11.5 (SD) g wet weight. The lobar venous
effluent drained back into the reservoir, the height of which was
adjusted to set the venous pressure at 4.5 ± 0.7 mmHg. Lobar
arterial, venous, and bronchial pressures were monitored continuously.
The vascular pressures were referenced to the level of the X-ray focal
spot, i.e., the center of the field of view of the X-ray image. Under
the control conditions, lobar arterial pressure was 14.5 ± 0.7 mmHg for blood-perfused lobes and 12.4 ± 0.7 mmHg for
plasma-perfused lobes.
The lobe was ventilated with a gas mixture containing ~15%
O2-5.6% CO2-balance N2. This
resulted in a PO2 of 120 ± 11 Torr, PCO2 of 41 ± 4 Torr, and pH of 7.31 ± 0.04 in the blood or plasma perfusate. Tidal volume was 136 ± 29 ml, and breathing frequency was 16.4 ± 2.6 breaths/min.
End-expiratory pressure was maintained at 4.2 ± 0.5 mmHg by using
a water overflow system.
To determine arterial diameters under the various experimental
conditions, the inflow tubing included an injection loop that allowed
the introduction of a 4-ml bolus of radiopaque contrast medium, 61%
isopamidol (Isovue 300), into the lobar arterial inflow without
affecting the pressure or flow (1). Before each bolus injection, the ventilation was halted at end expiration, and the bolus
was injected within 1 s. The reported vascular pressures were also
measured during this expiratory pause.
Once the preparation of the lobe was completed and the perfusion
pressure was stabilized, the ventilator was stopped at end expiration,
and a bolus was injected under "control" conditions. Then, to study
the dilatory effects of NO inhalation, it was necessary to constrict
the vessels. This was accomplished by continuous infusion of serotonin
(20-200 µg/min) into the arterial cannula. The infusion rate was
adjusted to produce an increase in perfusion pressure of
~30-40% with flow constant. With the level of constriction during serotonin infusion established, another bolus was injected. Then, NO was added to the inspired gas mixture by mixing 7,500 parts/million (ppm) NO in N2 with a bias flow stream of
O2, CO2, and N2 to obtain
concentrations of 30, 120, 480, or 960 ppm in the gas mixture at the
inflow to the piston respirator. It took ~20 s from the time the NO
was added to the ventilating gas until the lobar arterial pressure had
stabilized at its new lower level, and between 45 and 60 s after
the addition of NO, another bolus was injected. The lungs were then
ventilated with the NO-free gas mixture until the perfusion pressure
returned to a steady level, and another bolus was injected. This
procedure was repeated for each of the four NO concentrations in random
order of NO concentration. The entire sequence involving 12 bolus
injections (including the one under control conditions before the
serotonin infusion and two at the end after recovery from the serotonin
infusion) took ~36 min. The sequence was carried out one, two, or
three times on an individual lung lobe.
We also exposed the lung lobes to the highest NO concentration without
infusing serotonin to determine whether there was any NO-reversible
baseline tone in the vessels, even without the added constrictor
stimulus. Any decrease in perfusion pressure was <1 mmHg, consistent
with previous observations (1, 2) that the vessels in this
preparation have little tone unless an external stimulus is applied.
For each bolus of contrast medium passing through the pulmonary
vasculature, video images were recorded at 30 frames/s using an S-VHS
videocassette recorder. The diameter of the field of view at the
magnification settings used ranged from ~4.5 cm in diameter at low
magnification to 0.32 cm at high magnification. The recorded images
were analyzed off-line to determine the internal diameters of 4-20
vessels per field of view, with the number depending on the number of
measurable vessels in the field of view, which in turn depended on
magnification and vascular architecture in the particular field. For
each diameter measurement, a region of interest was placed over the
image of the vessel, and the videotape automatically advanced frame by
frame until the frame having maximum absorbance during the passage of
the contrast medium was identified. The average background image,
calculated by averaging image pixel intensities for 10 image frames
before the appearance of the contrast bolus, was subtracted from the
maximum absorbance image. Line scans orthogonal to the axis of the
vessel shadow were obtained, and the diameter was estimated from the
measured absorbance data using the previously described cylindric
model-based algorithm (4, 8). A "measurable" vessel
was one for which convergence of the optimization routine was obtained
when the vessel was at its smallest (i.e., serotonin constricted)
diameter. Some vessels were narrowed to such an extent during serotonin
infusion that, even if still visible, they were not measurable by this
criterion. The two control injections at the end of the sequence were
used to calibrate the imaging system for calculating vessel diameters in micrometers. These two injections were carried out with the lung at
two different positions a measured distance apart on a line
perpendicular to the X-ray beam. This measured distance (µm) was
divided by the fraction of the total image diameter moved by the
subject vessel across the image to obtain the calibration factor for
that vessel.
In all, 2,748 diameter measurements were made on 229 vessels (117 and
112 in the blood and plasma groups, respectively). The range of vessel
diameters under the control conditions was from ~300 to 3,400 µm.
The control diameter (Dc) of a vessel was taken to be the diameter before serotonin infusion. This was compared with
the average of the two diameters bracketing each NO exposure to obtain
the serotonin response for comparison with the diameter during NO
inhalation, as described below.
To determine the effect of NO inhalation on the pulmonary vascular
resistance in the intact dog, each of two dogs (10.4 and 13.0 kg body
wt) was anesthetized with pentobarbital sodium (30 mg/kg iv). An
endotracheal tube was placed and attached to a bias flow system that
allowed administration of inspired NO to the spontaneously breathing
dog. A balloon catheter was positioned in a pulmonary artery via an
external jugular vein such that balloon inflation resulted in a rapid
fall in catheter tip pressure to the arterial wedge pressure. Catheters
were also placed in each femoral artery and in a femoral vein. The tip
of the femoral venous catheter was advanced to the vena cava near the
entrance to the right atrium. After placement of the catheters, the dog
was heparinized (1,250 IU/kg). One femoral arterial catheter was used
to monitor systemic arterial pressure. The other was connected to a
Gilford dye densitometer via a roller pump so that the concentration of indocyanine green dye could be monitored in the arterial blood. The
pump flow rate was set at 20 ml/min, and the blood was returned via the
femoral venous catheter. The femoral venous catheter was also used to
inject 0.5-ml boluses containing indocyanine green dye (0.5 mg) for
measurement of the cardiac output. For the cardiac output calculation,
the area under the indocyanine green dye concentration curve was
determined after semilogarithmic extrapolation of the downslope of the
concentration vs. time curve in the usual fashion.
The protocol used to determine the pulmonary vascular resistance vs. NO
concentration relationship in the intact dogs was similar to that for
the isolated lungs. Mean pulmonary arterial pressure, wedge pressure,
and cardiac output were measured under control conditions. Then an
infusion of serotonin was begun at 41 or 102 µg/min via the femoral
venous catheter to increase the pulmonary arterial wedge pressure
difference by ~7 mmHg. The pressure and cardiac output measurements
were repeated, and NO was introduced into the inspired air at a
concentration of 30, 120, 480, or 960 ppm, and the measurements were
repeated. This sequence was repeated until all four NO concentrations
had been delivered and bracketed by measurements with no NO in the
inspired gas. The pulmonary vascular resistance was calculated as the
pulmonary arterial-wedge pressure difference divided by the cardiac output.
 |
RESULTS |
The patterns of the perfusion pressure (arterial-venous pressure
difference) response to serotonin infusion and to NO inhalation during
serotonin infusion at each stage of the experimental protocol for both
blood- and plasma-perfused lung lobes are shown in Fig. 1. The "control" perfusion pressure
and increases in perfusion pressure resulting from serotonin infusion
were greater during blood than plasma perfusion as expected because of
the higher blood viscosity. The symmetry of the "M" shape of the
pressure graphs reflects the extent of reversibility of the NO and
serotonin responses. The differences in the pressure responses to NO
inhalation are emphasized by the Fig. 2
representation, wherein the fraction of the serotonin-induced increase
in perfusion pressure reversed by NO inhalation is graphed. A one-way
analysis of variance with repeated measures within blood or plasma
groups reveals a significant NO concentration-dependent reversal of the
serotonin-induced pressure increase within both blood-
(P < 0.004) and plasma-perfused lungs (P < 0.001). A two-way analysis of variance between
blood and plasma indicated that mean reversal of the serotonin response by NO inhalation was greater (P < 0.001) in the
plasma- than in the blood-perfused group after allowing for the effects
of NO concentration.

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 1.
Pulmonary arterial-venous pressure differences (Pa Pv) at each phase of the experimental protocol. Values are
means ± SE for the 7 blood-perfused lungs and 8 plasma-perfused
lungs. 5HT, pressure measured during infusion of serotonin
(5-hydroxytryptamine); 5HT+NO, pressure measured when the indicated
concentration of nitric oxide (NO) was inhaled during the serotonin
infusion; ppm, parts/million. Control pressures were obtained with
neither serotonin infusion nor NO inhalation.
|
|

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 2.
Average (± SE) fraction of the perfusion pressure
increase in response to serotonin infusion that was reversed by NO
inhalation for the 4 NO concentrations. There was a significant NO
concentration effect in both groups, and the response to a given NO
concentration in the blood-perfused lungs was significantly smaller
than that in the plasma-perfused lungs (see text).
|
|
To provide a sense of the raw image data, example images from three
stages of the experimental protocol from one low magnification field of
view of a perfused lung lobe are shown in Fig.
3. The narrowing of the vessels resulting
from the serotonin infusion and the dilation resulting from NO
inhalation during serotonin infusion are evident.

View larger version (64K):
[in this window]
[in a new window]
|
Fig. 3.
Example X-ray images of a portion of the arterial tree of
a dog lung lobe under control conditions, during serotonin infusion
(5HT), and during serotonin infusion with 480 ppm NO in the ventilating
gas mixture (5HT + 480 ppm NO).
|
|
The goal of the serotonin infusion was to achieve constriction
throughout the measurable diameter range so that the NO-induced dilation could be measured. The mean decreases in diameter were 22.8 ± 14.5 (SD) % for blood- and 21.3 ± 10.0% for
plasma-perfused lung lobe. The changes in diameter in response to
serotonin (5-hydroxytryptamine) infusion
(
D5-HT) for the vessels grouped into four
bins according to vessel diameter are shown in Fig.
4. Because all of the vessels did not
narrow by the same fraction in response to serotonin infusion, but
there was not a significant correlation between
D5-HT and the change in diameter in response
to inhaled NO (
DNO) for any NO concentration,
the NO-induced dilation is represented by the ratio of
DNO to
D5-HT
(
DNO/
D5-HT) in
Figs. 5 and
6. The relationships between individual
DNO/
D5-HT and their
respective Dc were evaluated by using Eq. 1 for each NO concentration
|
(1)
|
where Dc is in µm, and the
mi are the fitting coefficients. The sigmoid
form of Eq. 1 was chosen because the range of
DNO/
D5-HT is
constrained by the fact that the maximum diameter of a vessel is
approximately equal to Dc and the minimum
diameter cannot be much smaller than that resulting from the initial
serotonin constriction in the absence of NO. In actuality, the latter
is not a true minimum because a further decrease in large vessel
diameter in response to NO is possible because of the fact that, with
constant flow, downstream dilation reduces upstream pressure. Thus the
offset, m1, was included.

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 4.
Serotonin-induced constriction of the pulmonary arteries
in the diameter range studied. The vertical scale is the fractional
decrease in diameter, D5-HT. The symbols
represent the means ± SE of bins ranging in size from 16 to 47 vessels.
|
|

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 5.
Effect of inhaled NO concentration on the diameter
dependence of the NO-induced reversal of the serotonin-induced
constriction. The vertical scale is the fraction of the
serotonin-induced vasoconstriction, D5-HT,
that was reversed by NO, DNO. The symbols
represent the means ± SE of the data in the same bins as in Fig.
4 for the designated NO concentrations of 30, 120, 480, and 960 ppm.
The lines are Eq. 1 fit to the individual vessel data. The
NO concentration effect was significant for both blood and plasma
perfusion (see text).
|
|

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 6.
Effect of plasma vs. blood perfusion on the diameter
dependence of the NO-induced reversal of the serotonin-induced
constriction in the same format as Fig. 5. Values are means ± SE.
The difference between blood and plasma was significant at each NO
concentration (see text).
|
|
Equation 1 fits to the individual data points, and the
averaged data grouped into the four bins by Dc
are plotted to emphasize the NO concentration effects in Fig. 5 and to
emphasize the difference between blood and plasma in Fig. 6. The
fitting coefficients are given in Table
1. Equation 1 represented the
data significantly better than did the mean in each case (F
test, P < 0.001). The rightward shifts with increasing
NO concentration and removal of the blood cells reflect the dilation of
larger arteries. The statistical significance of the NO concentration
dependence was evaluated by comparing the variances about Eq. 1 fitted to the pooled data (either blood or plasma) with those
obtained from the fits to the data for the individual NO concentrations
(19). Similarly, for each NO concentration, the plasma vs.
blood comparison was made by comparing the variances about the pooled
data fits to the blood or plasma fits. The F test revealed a
significant NO concentration effect within both plasma- and
blood-perfused groups (P < 0.001), and the blood vs.
plasma difference was significant at all NO concentrations (30 ppm,
P < 0.05; 120 ppm, P < 0.001; 480 and
960 ppm, P < 0.01). Equation 1 provides a
means for making these comparisons and for summarizing the trends in
the data, but the mi are too highly correlated
in the fitting procedure to have specific physical or physiological
interpretations. Similarly, extrapolation beyond the diameter range
studied would not appear to be justified.
The vascular resistance data for the intact dogs are graphed in Figs.
7 and 8
in a similar fashion to the pressure data for the isolated lungs in
Figs. 1 and 2. They suggest that the total vascular resistance response
to a given NO concentration was about the same in the intact animals as
in the isolated lungs.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 7.
Pulmonary vascular resistance (means ± SE;
n = 2) in the intact dogs plotted in a fashion similar
to Fig. 1.
|
|

View larger version (12K):
[in this window]
[in a new window]
|
Fig. 8.
Fraction (means ± SE; n = 2) of the
pulmonary vascular resistance increase in response to serotonin
infusion that was reversed by NO inhalation for the 4 NO concentrations
in the intact dogs plotted in a fashion similar to Fig. 2.
|
|
 |
DISCUSSION |
The results reveal a NO concentration and diameter-dependent
vasodilatory effect of inhaled NO in dog pulmonary arteries and provide
quantification of the relationships in the diameter range studied. This
study has some similarities to the elegant study of Shirai et al.
(28), wherein the arterial diameter responses to inhaled
NO in cat lung pulmonary arteries with basal tone and with additional
tone induced by alveolar hypoxia were studied. That study demonstrated
that inhaled NO affected pulmonary arteries in cat lungs in the ~100-
to 1,000-µm-diameter range. Adding 40 ppm NO in the inhaled air
eliminated the hypoxic vasoconstriction throughout the measured
diameter range, indicating that inhaled NO has access to the vascular
smooth muscle of vessels in the entire range of diameters also affected
by alveolar PO2. The present study differs in
the species and vasoconstrictor stimulus used. The dog lung extends the
diameter range available for study, but, more importantly for the
objectives of the present study, its pulmonary arteries are essentially
devoid of basal tone in this experimental preparation (1,
2). Basal tone would have a potentially confounding effect
because it would be difficult to rule out the possibility that any
diameter dependence of the NO response is simply a reflection of the
diameter dependence of the basal tone. The use of the infused
vasconstrictor stimulus (serotonin), as opposed to ventilation with low
oxygen, tends to separate the question of NO access from that of
constrictor stimulus access. The asymmetry between the
serotonin-induced constriction and NO-induced dilation implies
diameter-dependent NO accessibility to the serotonin-activated smooth
muscle cells. Although a contribution by some other factor(s), such as
a vessel size-dependent gradient in the NO transduction mechanism
[e.g., in soluble guanylate cyclase activity (6)],
cannot be ruled out, the progressive rightward shift with increasing NO
concentration suggests that saturation of the vasodilator mechanism did
not play a dominant role in determining the
DNO/
D5-HT vs.
Dc relationship.
The NO concentrations used were high compared with concentrations
commonly used in inhalation therapy (29) or to reverse experimental hypoxic vasoconstriction (24, 28). Although
it is not surprising that it would take relatively high concentrations of NO to affect large vessels, we were somewhat surprised by the high
NO concentrations required to achieve a maximum effect on total
pulmonary vascular resistance in the blood-perfused lungs. In this
regard, the NO concentration-response relationship for reversing the
serotonin-induced increase in total pulmonary vascular resistance in
the dog lungs was similar to that for reversing the angiotensin
II-induced resistance increase in rat lungs (21). Because
the rat lung study was also carried out in isolated lungs, we
considered the possibility that the NO concentration-total vascular
resistance response might be somehow shifted in isolated lungs compared
with that in the intact animals used in other studies (24, 28,
29). However, we found that the pulmonary vascular resistance
concentration-response relationship was not substantially different in
the intact dogs. Thus isolation of the lungs does not appear to be the
important variable, and a more likely possibility seems to be related
to the size of the constricted vessels. We used serotonin specifically
to obtain constriction over a wider range in diameters than what is
obtained, for example, with alveolar hypoxia (1). Most of
the vessels in the size range studied apparently make relatively little
contribution to the total vascular resistance under control conditions
(1). This can be appreciated by noting that the ~20%
average decrease in diameters resulting from serotonin infusion would
have increased the resistance of these vessels by >140%, assuming
that resistance is inversely proportional to the fourth power of
diameter, whereas total lobar vascular resistance increased by only
~40% (see Fig. 1). Thus the upper bound on their possible
contribution to the total resistance under control conditions would be
<30% [i.e., 40/140 (1)], assuming that the vessels
that were not measured did not increase their resistance in response to
serotonin. On the other hand, the observation that both narrowing of
large vessels and elevated total vascular resistance remained, even
when the NO concentration was high, suggests that the vessels in the
measured size range made a substantial contribution to the increase
caused by serotonin.
Removing blood cells has been observed to augment the decrease in total
pulmonary vascular resistance induced by inhaled NO (21)
and the transmission of the dilatory effects of inhaled NO downstream
from the pulmonary capillaries (21, 22, 25). This is
presumed to reflect the NO scavenging effects of the hemoglobin (14, 21, 22, 25). In the present study, the plasma
experiments were motivated by consideration of the possibility that, by
removing the intravascular sink for NO, the vascular smooth muscle NO
concentration would be increased at a given inhaled NO concentration.
Thus a flattening of the NO diffusion gradient between the air spaces and the perfusate might allow the NO access to larger, further upstream
vessels. The results appear to be consistent with that possibility and
suggest that gas exchange through the walls of fairly large arteries
can in fact have a significant effect on their smooth muscle response
to intrapulmonary gas composition. Thus the implication of the effect
of removing the blood cells is that there is sufficient NO transport
between pulmonary gas and blood in arteries in the NO responsive size
range such that removing the hemoglobin increased the NO concentration
within the smooth muscle cells.
In conclusion, we have measured the pulmonary arterial diameter
dependence of the dilator effect of inhaled NO. The results have
implications with regard to vessel accessibility and the efficacy of
inhaled NO in pulmonary vasodilator therapy. However, in addition, the
expectation is that the data will provide part of the database for
modeling of the influence of exchange of gases between intrapulmonary
air and pulmonary arterial blood on pulmonary arterial tone. In that
context, the serotonin-activated vascular smooth muscle might be
thought of as a NO sensor situated between the gas and blood.
 |
ACKNOWLEDGEMENTS |
This study was supported by National Institutes of Health Grants
RO1-HL-19298, T32-HL-07852, and T32-GM-O837706, and by the Department
of Veterans Affairs.
 |
FOOTNOTES |
Address for reprint requests and other correspondence: C. A. Dawson, Research Service 151, Zablocki VAMC, 5000 West National Ave.,
Milwaukee, WI 53593 (E-mail: cdawson{at}mcw.edu).
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement"
in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 1 May 2001; accepted in final form 22 June 2001.
 |
REFERENCES |
1.
Al-Tinawi, A,
Krenz GS,
Rickaby DA,
Linehan JH,
and
Dawson CA.
Influence of hypoxia and serotonin on small pulmonary vessels.
J Appl Physiol
76:
56-64,
1994[Abstract/Free Full Text].
2.
Al-Tinawi, A,
Madden JA,
Dawson CA,
Linehan JH,
Harder DR,
and
Rickaby DA.
Distensibility of small arteries of the dog lung.
J Appl Physiol
71:
1714-1722,
1991[Abstract/Free Full Text].
3.
Clough, AV,
Haworth ST,
Hanger CC,
Wang J,
Roerig DL,
Linehan JH,
and
Dawson CA.
Transit time dispersion in the pulmonary arterial tree.
J Appl Physiol
85:
565-574,
1998[Abstract/Free Full Text].
4.
Clough, AV,
Krenz GS,
Owens M,
Al-Tinawi A,
Dawson CA,
and
Linehan JH.
An algorithm for angiographic estimation of blood vessel diameter.
J Appl Physiol
71:
2050-2058,
1991[Abstract/Free Full Text].
5.
Conhaim, RL,
and
Staub NC.
Reflection spectrophotometric measurement of O2 uptake in pulmonary arterioles of cats.
J Appl Physiol
48:
848-856,
1980[Abstract/Free Full Text].
6.
D'Angelis, CA,
Nickerson PA,
Steinhorn RH,
and
Morin FC, 3rd.
Heterogeneous distribution of soluble guanylate cyclase in the pulmonary vasculature of the fetal lamb.
Anat Rec
250:
62-69,
1998[Medline].
7.
Dawson, CA.
Role of pulmonary vasomotion in the physiology of the lung.
Physiol Rev
64:
544-616,
1984[Free Full Text].
8.
Dawson, CA,
Krenz GS,
Karau KL,
Haworth ST,
Hanger CC,
and
Linehan JH.
Structure-function relationships in the pulmonary arterial tree.
J Appl Physiol
86:
569-583,
1999[Abstract/Free Full Text].
9.
Feisal, KA,
Soni J,
and
DeBois AB.
Pulmonary arterial circulation time, pulmonary arterial blood volume, and the ratio of gas to tissue in the lungs of dogs.
J Clin Invest
41:
390-400,
1962.
10.
Frostell, C,
Fratacci MD,
Wain JC,
Jones R,
and
Zapol WM.
Inhaled nitric oxide: a selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction.
Circulation
83:
2038-2047,
1991[Abstract/Free Full Text].
11.
Gordon, JB,
Halla TR,
Fike CD,
and
Madden JA.
Mediators of alkalosis-induced relaxation in pulmonary arteries from normoxic and chronically hypoxic piglets.
Am J Physiol Lung Cell Mol Physiol
276:
L155-L163,
1999[Abstract/Free Full Text].
12.
Hauge, A.
Hypoxia and pulmonary vascular resistance. The relative effects of pulmonary arterial and alveolar PO2.
Acta Physiol Scand
76:
121-130,
1969[ISI][Medline].
13.
Hillier, SC,
Graham JA,
Hanger CC,
Godbey PS,
Glenny RW,
and
Wagner WW.
Hypoxic vasoconstriction in pulmonary arterioles and venules.
J Appl Physiol
82:
1084-1090,
1997[Abstract/Free Full Text].
14.
Ignarro, LJ,
Cirino G,
Casini A,
and
Napoli C.
Nitric oxide as a signaling molecule in the vascular system: an overview.
J Cardiovasc Pharmacol
34:
879-886,
1999[ISI][Medline].
15.
Jameson, AG.
Gaseous diffusion from alveoli into pulmonary arteries.
J Appl Physiol
19:
448-456,
1964[Abstract/Free Full Text].
16.
Madden, J,
Dawson CA,
and
Harder DA.
Hypoxia-induced activation in small isolation pulmonary arteries from the cat.
J Appl Physiol
59:
113-118,
1985[Abstract/Free Full Text].
17.
Madden, JA,
Vadula MS,
and
Kurup VP.
Effects of hypoxia and other vasoactive agents on pulmonary and cerebral artery smooth muscle cells.
Am J Physiol Lung Cell Mol Physiol
263:
L384-L393,
1992[Abstract/Free Full Text].
18.
Marshall, C,
and
Marshall B.
Site and sensitivity for stimulation of hypoxic pulmonary vasoconstriction.
J Appl Physiol
55:
711-716,
1983[Abstract/Free Full Text].
19.
Motulsky, NJ,
and
Ransnas LA.
Fitting curves to data using nonlinear regression.
FASEB J
1:
365-374,
1987[Abstract].
20.
Rhodin, JAG
Microscopic anatomy of the pulmonary vascular bed in the cat lungs.
Microvasc Res
15:
169-193,
1978[ISI][Medline].
21.
Rich, GF,
Roos CM,
Anderson SM,
Urich DC,
Daugherty MO,
and
Johns RA.
Inhaled nitric oxide: dose response and the effects of blood in the isolated rat lung.
J Appl Physiol
75:
1278-1284,
1993[Abstract/Free Full Text].
22.
Rimar, S,
and
Gillis CN.
Selective pulmonary vasodilation by inhaled nitric oxide is due to hemoglobin inactivation.
Circulation
88:
2884-2887,
1993[Abstract/Free Full Text].
23.
Rimar, S,
and
Gillis CN.
Site of pulmonary vasodilation by inhaled nitric oxide in the perfused lung.
J Appl Physiol
78:
1745-1749,
1995[Abstract/Free Full Text].
24.
Romand, J,
Pinsky MR,
Firestone L,
Zar HA,
and
Lancaster JRJ
Inhaled nitric oxide partially reverses hypoxic pulmonary vasoconstriction in the dog.
J Appl Physiol
76:
1350-1355,
1994[Abstract/Free Full Text].
25.
Roos, CM,
Rich GF,
Uncles DR,
Daugherty MO,
and
Frank DU.
Sites of vasodilation by inhaled nitric oxide vs. sodium nitroprusside in endothelin-constricted isolated rat lungs.
J Appl Physiol
77:
51-57,
1994[Abstract/Free Full Text].
26.
Sackner, M,
Feisal K,
and
Karsch D.
Size of gas exchange vessels in the lung.
J Clin Invest
43:
1847-1855,
1964.
27.
Shirai, M,
Sada K,
and
Ninomiya I.
Effects of regional alveolar hypoxia and hypercapnia in small pulmonary vessels in cats.
J Appl Physiol
61:
440-448,
1986[Abstract/Free Full Text].
28.
Shirai, M,
Shimouchi A,
Kawaguchi AT,
Sunagawa K,
and
Ninomiya I.
Inhaled nitric oxide: diameter response patterns in feline small pulmonary arteries and veins.
Am J Physiol Heart Circ Physiol
270:
H974-H980,
1996[Abstract/Free Full Text].
29.
Steudel, W,
Hurford WE,
and
Zapol WM.
Inhaled nitric oxide: basic biology and clinical applications.
Anesthesiology
91:
1090-1121,
1999[ISI][Medline].
30.
Yuan, XY,
Goldman WF,
Tod ML,
Rubin LJ,
and
Blaustein MP.
Hypoxia reduces potassium currents in cultured rat pulmonary but not mesenteric arterial myocytes.
Am J Physiol Lung Cell Mol Physiol
264:
L116-L123,
1993[Abstract/Free Full Text].
J APPL PHYSIOL 91(5):1948-1954